Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaroxaban versus Vitamin K Antagonists: A French Nationwide Propensity-Matched Cohort Study
نویسنده
چکیده
Running title: Maura et al.; Comparative effectiveness and safety of NOAC 2 De De Dept pt pt of f f Ep Ep Epidem m mi io i logy of Health Products, Fren n n h ch h h National Agen e e cy f f for or or Medicines and Health Pr Pr Prod od odu u ucts ts ts S S Saf af afet e y y (A (A (AN N NSM M), , Sa a ain in int t t-De De Deni ni n s, s, s, F F Fra ra ranc nc nce e e Abstract Background—The safety and effectiveness of Non-VKA Oral AntiCoagulants (NOAC),
منابع مشابه
Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaroxaban Versus Vitamin K Antagonists
BACKGROUND The safety and effectiveness of non-vitamin K antagonist (VKA) oral anticoagulants, dabigatran or rivaroxaban, were compared with VKA in anticoagulant-naive patients with nonvalvular atrial fibrillation during the early phase of anticoagulant therapy. METHODS AND RESULTS With the use of the French medico-administrative databases (SNIIRAM and PMSI), this nationwide cohort study incl...
متن کاملComparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran and rivaroxaban: results from the CRAFT study.
BACKGROUND The first line drugs for treatment of non-valvular atrial fibrillation (AF) are non-vitamin K oral anticoagulants (NOACs), which are preferred over vitamin K antagonists (VKAs). There is some evidence that an everyday clinical practice is distant from the guidelines. AIM The study aimed to compare characteristics of patients on VKAs, dabigatran and rivaroxaban met in everyday pract...
متن کاملEffectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
BACKGROUND The introduction of non-vitamin K antagonist oral anticoagulants has been a major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in clinical trials may not translate to routine practice. We aimed to evaluate the effectiveness and safety of dabigatran, rivaroxaban, and apixaban by comparing each agent with warfarin. METHODS AND RESULTS Using a large...
متن کاملAdherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study
PURPOSE Direct oral anticoagulants (DOACs) have been promoted in patients with nonvalvular atrial fibrillation (nv-AF) as a more convenient alternative to vitamin K antagonists. We estimated 1-year dabigatran and rivaroxaban adherence rates in nv-AF patients and assessed associations between baseline patient characteristics and nonadherence. METHODS This cohort study included OAC-naive nv-AF ...
متن کاملRisk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation – Data from the Ljubljana Registry
BACKGROUND AND AIM Interruption of anticoagulant treatment with warfarin or non-vitamin K antagonist oral anticoagulants (NOAC) represents a vulnerable period with an increased risk of thromboembolic events. What is the incidence of thromboembolic events in real-life patients with non-valvular atrial fibrillation treated with NOAC who had a discontinuation or cessation of treatment in compariso...
متن کامل